ArticleBMC genomics2017
A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data.
Article in BMC genomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 3 syntheses or guidelines pooled it, 239 citations in OpenAlex.
- New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.Briefings in bioinformatics · 2024Pooled it
- Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses.PloS one · 2023Pooled it
- Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases.Medical science monitor : international medical journal of experimental and clinical research · 2018Pooled it
- Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets.The Journal of clinical investigation · 2019Trial
- PhenoMapR: scalable mapping of sample phenotypes to single-cell, spatial, and bulk transcriptomics data.bioRxiv : the preprint server for biology · 2026Article
- Machine Learning-Based Identification of Candidate Serum miRNA Features for Pan-Cancer and Cancer Type Classification.Life (Basel, Switzerland) · 2026Article
- Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.Cell reports. Medicine · 2026Article
- Pan-Cancer Analysis of ANO6 and Experimental Validation in Metastatic Melanoma.Biochemical genetics · 2026Article
- Article
- Machine learning-driven gene expression profiling for lung cancer stage determination.Cancer biomarkers : section A of Disease markers · 2025Article
- HallmarkGraph: a cancer hallmark informed graph neural network for classifying hierarchical tumor subtypes.Bioinformatics (Oxford, England) · 2025Article
- A three-subtype prognostic classification based on base excision repair and oxidative stress genes in lung adenocarcinoma and its relationship with tumor microenvironment.Scientific reports · 2025Article
- Deep profiling of gene expression across 18 human cancers.Nature biomedical engineering · 2025Article
- AutoTFCNNY: A multi-instance neural network for enhanced early cancer detection using TCR data.PloS one · 2025Article
- Exosomal microRNA signatures in youth at clinical high risk for bipolar disorder.Frontiers in psychiatry · 2025Article
- A comparative analysis of gene expression profiling by statistical and machine learning approaches.Bioinformatics advances · 2025Article
- Computational models for pan-cancer classification based on multi-omics data.Frontiers in genetics · 2025Review
- Emerging Signatures of Hematological Malignancies from Gene Expression and Transcription Factor-Gene Regulations.International journal of molecular sciences · 2024Article
- A deep profile of gene expression across 18 human cancers.bioRxiv : the preprint server for biology · 2024Article
- From molecular subgroups to molecular targeted therapy in rheumatoid arthritis: A bioinformatics approach.Heliyon · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe Cancer Genome Atlas (TCGA) has generated comprehensive molecular profiles. We aim to identify a set of genes whose expression patterns can distinguish diverse tumor types. Those features may serve as biomarkers for tumor diagnosis and drug development.
methodsUsing RNA-seq expression data, we undertook a pan-cancer classification of 9,096 TCGA tumor samples representing 31 tumor types. We randomly assigned 75% of samples into training and 25% into testing, proportionally allocating samples from each tumor type.
resultsWe could correctly classify more than 90% of the test set samples. Accuracies were high for all but three of the 31 tumor types, in particular, for READ (rectum adenocarcinoma) which was largely indistinguishable from COAD (colon adenocarcinoma). We also carried out pan-cancer classification, separately for males and females, on 23 sex non-specific tumor types (those unrelated to reproductive organs). Results from these gender-specific analyses largely recapitulated results when gender was ignored. Remarkably, more than 80% of the 100 most discriminative genes selected from each gender separately overlapped. Genes that were differentially expressed between genders included BNC1, FAT2, FOXA1, and HOXA11. FOXA1 has been shown to play a role for sexual dimorphism in liver cancer. The differentially discriminative genes we identified might be important for the gender differences in tumor incidence and survival.
conclusionsWe were able to identify many sets of 20 genes that could correctly classify more than 90% of the samples from 31 different tumor types using TCGA RNA-seq data. This accuracy is remarkable given the number of the tumor types and the total number of samples involved. We achieved similar results when we analyzed 23 non-sex-specific tumor types separately for males and females. We regard the frequency with which a gene appeared in those sets as measuring its importance for tumor classification. One third of the 50 most frequently appearing genes were pseudogenes; the degree of enrichment may be indicative of their importance in tumor classification. Lastly, we identified a few genes that might play a role in sexual dimorphism in certain cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.